OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
160A$1993.0058

As Partners Co Ltd

Healthcare Facilities & ServicesVerified

As Partners Co Ltd maintains a liquidity position with a current ratio of 1.83, indicating the company can cover its short-term liabilities with its short-term assets. The company's price-to-book ratio of 1.72 suggests that the market values the company at a premium to its book value, while the debt-to-equity ratio of 2.24 indicates a relatively high level of leverage. The company's profitability is reflected in its return on equity of 22.98%, which is a strong indicator of how effectively the company is using shareholders' equity to generate profits. However, the return on assets of 4.47% suggests that the company is not as efficient in using its total assets to generate earnings. As Partners Co Ltd's business is divided into two segments: the Senior Business and the Real Estate business. The Senior Business is the primary source of revenue, focusing on nursing care services for the elderly. The Real Estate business, which includes the development of nursing care homes and the revitalization of aging real estate, contributes to the company's diversified revenue streams. The company's growth trajectory is expected to be positive, with analysts forecasting a mean revenue estimate of 24,000,000,000 JPY for the upcoming fiscal year, compared to the last actual revenue of 17,917,000,000 JPY. This indicates a potential growth of approximately 34% in revenue. The risk assessment for As Partners Co Ltd indicates a medium level of liquidity risk, with a key flag noting that net cash is negative after subtracting total debt. The company's dilution risk is assessed as low, suggesting that there is minimal threat to shareholder value from new share issuances. Recent events and filings show that the company has a strong earnings performance, with the last actual EPS of 269.74 JPY, slightly below the mean EPS estimate of 296.00 JPY. This suggests that the company is performing in line with analyst expectations, with a slight underperformance in earnings.

30-day price · 160A+15.00 (+0.7%)
Low$1928.00High$2255.00Close$2143.00As of22 May, 00:00 UTC
Profile
CompanyAs Partners Co Ltd
Ticker160A.T
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. As Partners Co Ltd operates in the healthcare facilities and services industry, providing nursing care services to elderly individuals through assisted living homes, day services, and short stays, while also engaging in real estate development and management focused on senior care facilities.

Classification. As Partners Co Ltd is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92 based on verified market data.

As Partners Co Ltd maintains a liquidity position with a current ratio of 1.83, indicating the company can cover its short-term liabilities with its short-term assets. The company's price-to-book ratio of 1.72 suggests that the market values the company at a premium to its book value, while the debt-to-equity ratio of 2.24 indicates a relatively high level of leverage. The company's profitability is reflected in its return on equity of 22.98%, which is a strong indicator of how effectively the company is using shareholders' equity to generate profits. However, the return on assets of 4.47% suggests that the company is not as efficient in using its total assets to generate earnings. As Partners Co Ltd's business is divided into two segments: the Senior Business and the Real Estate business. The Senior Business is the primary source of revenue, focusing on nursing care services for the elderly. The Real Estate business, which includes the development of nursing care homes and the revitalization of aging real estate, contributes to the company's diversified revenue streams. The company's growth trajectory is expected to be positive, with analysts forecasting a mean revenue estimate of 24,000,000,000 JPY for the upcoming fiscal year, compared to the last actual revenue of 17,917,000,000 JPY. This indicates a potential growth of approximately 34% in revenue. The risk assessment for As Partners Co Ltd indicates a medium level of liquidity risk, with a key flag noting that net cash is negative after subtracting total debt. The company's dilution risk is assessed as low, suggesting that there is minimal threat to shareholder value from new share issuances. Recent events and filings show that the company has a strong earnings performance, with the last actual EPS of 269.74 JPY, slightly below the mean EPS estimate of 296.00 JPY. This suggests that the company is performing in line with analyst expectations, with a slight underperformance in earnings.
Key takeaways
  • As Partners Co Ltd has a strong return on equity of 22.98%, indicating effective use of shareholders' equity to generate profits.
  • The company's debt-to-equity ratio of 2.24 suggests a high level of leverage, which could pose a risk in a rising interest rate environment.
  • Analysts forecast a significant increase in revenue, projecting a 34% growth to 24,000,000,000 JPY for the upcoming fiscal year.
  • The company's liquidity position is stable, with a current ratio of 1.83, but its net cash position is negative after accounting for total debt.
  • The company's business is diversified across two segments, with the Senior Business being the primary revenue driver.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyJPY
Revenue$17.92B
Gross profit$3.87B
Operating income$1.30B
Net income$956.7M
R&D
SG&A
D&A
SBC
Operating cash flow$775.6M
CapEx-$4.61B
Free cash flow-$3.60B
Total assets$21.41B
Total liabilities$17.24B
Total equity$4.16B
Cash & equivalents$6.86B
Long-term debt$9.31B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$17.92B$1.30B$956.7M-$3.60B
FY-1$17.15B$803.2M$563.6M-$573.3M
FY-2$12.78B$199.0M$229.7M-$744.1M
FY-3$11.52B$233.2M$484.9M-$115.3M
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$21.41B$4.16B$6.86B
FY-1$15.95B$2.38B$5.71B
FY-2$14.74B$1.86B$4.02B
FY-3$11.81B$1.68B$3.86B
FY-4
PeriodOCFCapExFCFSBC
FY0$775.6M-$4.61B-$3.60B
FY-1$3.43B-$1.24B-$573.3M
FY-2-$745.2M-$1.12B-$744.1M
FY-3-$339.0M-$721.1M-$115.3M
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0$5.48B$79.1M$47.8M
FQ-1$4.62B$114.6M$92.0M
FQ-2$8.99B$1.41B$1.00B
FQ-3$3.76B-$6.6M$51.1M
FQ-4$3.57B$8.2M$1.5M
FQ-5$6.60B$1.32B$935.9M
FQ-6$3.99B-$19.8M-$31.8M
FQ-7$4.33B$157.4M$115.3M
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0$23.18B$5.12B$4.24B
FQ-1$21.15B$5.07B$6.99B
FQ-2$19.22B$4.97B$7.18B
FQ-3$21.41B$4.16B$6.86B
FQ-4$20.30B$4.10B$7.00B
FQ-5$18.13B$4.10B$7.22B
FQ-6$17.67B$3.16B$6.89B
FQ-7$15.95B$2.38B$5.71B
PeriodOCFCapExFCFSBC
FQ0
FQ-1$4.13B-$1.86B
FQ-2
FQ-3$775.6M-$4.61B
FQ-4
FQ-5$2.20B-$2.35B
FQ-6
FQ-7$3.43B-$1.24B
Valuation
Market price$1993.00
Market cap$7.15B
Enterprise value$9.60B
P/E7.5
Reported non-GAAP P/E
EV/Revenue0.5
EV/Op income7.4
EV/OCF12.4
P/B1.7
P/Tangible book1.7
Tangible book$4.16B
Net cash-$2.45B
Current ratio1.8
Debt/Equity2.2
ROA4.5%
ROE23.0%
Cash conversion81.0%
CapEx/Revenue-25.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric160AActivity
Op margin7.3%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin5.3%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin21.6%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue-25.7%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity224.0%71.3% medp25 60.7% · p75 71.3%top quartile
Observations
IR observations
Mean EPS estimate296.00 JPY
Last actual EPS269.74 JPY
Mean revenue estimate24,000,000,000 JPY
Last actual revenue17,917,000,000 JPY
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 01:49 UTC#2e3e98dc
Market quoteclose JPY 1993.00 · shares 0.00B diluted
no public URL
2026-05-12 01:49 UTC#3cbd6f63
Source: analysis-pipeline (hybrid)Generated: 2026-05-12 01:51 UTCJob: 73bbaf9e